Metastatic Breast Cancer — Expanded Access Programs
Overview
Right2Hope maintains a directory of 70 expanded access programs, clinical trials, and compassionate use pathways listed for Metastatic Breast Cancer. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with metastatic breast cancer programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 23 programs are currently active or recruiting, with the remaining 47 in other lifecycle stages. Sponsors actively running programs in this area include Memorial Sloan Kettering Cancer Center, BriaCell Therapeutics Corporation, Dana-Farber Cancer Institute, Eli Lilly and Company, Hoffmann-La Roche, and others.
By recruiting status
Snapshot of where every Metastatic Breast Cancer program currently sits in its lifecycle.
- Active / Recruiting23
- Inactive47
Top sponsors
Organisations running the most Metastatic Breast Cancer programs in the directory.
- Memorial Sloan Kettering Cancer Center8 programs
- BriaCell Therapeutics Corporation2 programs
- Dana-Farber Cancer Institute2 programs
- Eli Lilly and Company2 programs
- Hoffmann-La Roche2 programs
- Olema Pharmaceuticals, Inc.2 programs
- Stemline Therapeutics, Inc.2 programs
- University of Alabama at Birmingham2 programs
- American Society of Clinical Oncology1 program
- Ana C Garrido-Castro, MD1 program
Metastatic Breast Cancer programs (70)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study to Find the Best Dose of New Treatments BNT323 and BNT327 for Advanced Breast Cancer — BioNTech SE
- Study on ST101 for Patients with Advanced Solid Tumors — Sapience Therapeutics
- Study on T-DXd Combinations for HER2-positive Metastatic Breast Cancer — AstraZeneca
- Study on Abemaciclib with Tamoxifen or Alone for Women with Metastatic Breast Cancer — Eli Lilly and Company
- Study on Alisertib with Hormone Therapy for HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer — Puma Biotechnology, Inc.
- Study on Surgery and Radiation Therapy for People with Breast Cancer — Memorial Sloan Kettering Cancer Center
- Adaptive Therapy with Capecitabine for Treating Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer — Mayo Clinic
- Study on Elacestrant Alone or with a CDK4/6 Inhibitor for Advanced or Metastatic ER-positive/HER2-negative Breast Cancer — Northwestern University
- Study Comparing Lasofoxifene and Abemaciclib with Fulvestrant and Abemaciclib for Advanced ER+/HER2- Breast Cancer with ESR1 Mutation — Sermonix Pharmaceuticals Inc.
- Study on New Biomarker-Driven Treatments for Advanced Breast Cancer — UNC Lineberger Comprehensive Cancer Center
- Study on Olaparib for Treating Metastatic Breast Cancer — Beth Israel Deaconess Medical Center
- Study on Palazestrant and Ribociclib for First-time Treatment of ER+/HER2- Advanced Breast Cancer — Olema Pharmaceuticals, Inc.
- Study on Palbociclib After CDK and Endocrine Therapy for Breast Cancer (PACE) — Dana-Farber Cancer Institute
- Phase 3 Study Comparing RLY-2608 + Fulvestrant and Capivasertib + Fulvestrant for Advanced PIK3CA-mutant HR+/HER2- Breast Cancer — Relay Therapeutics, Inc.
- Phase II Study of Low Dose Capecitabine for Older or Frail Patients with Advanced Breast Cancer — University of Alabama at Birmingham
- Phase II Study of Chemotherapy with or without Erbitux for Metastatic Breast Cancer Patients — US Oncology Research
- Phase II Study Comparing Capecitabine and Elacestrant with Capecitabine Alone in ER+ Breast Cancer (CAPELA) — Kristina A. Fanucci
- Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer — Memorial Sloan Kettering Cancer Center
- Study on New Treatment Strategy for Metastatic Breast Cancer Using Approved Drugs — H. Lee Moffitt Cancer Center and Research Institute
- Study of Belzutifan Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer — Merck Sharp & Dohme LLC
- Study on Suprachoroidal Administration for Patients with Eye Metastasis from Breast or Lung Cancer — Aura Biosciences
- Study on CDK4/6 Inhibitor Dosing for Older Patients with Metastatic Breast Cancer — American Society of Clinical Oncology
- Study on Treating ADC-Refractory Breast Cancer with Dato-DXd or T-DXd: TRADE DXd — Ana C Garrido-Castro, MD
- Study on the Safety and Effectiveness of ConvitVax Vaccine for Metastatic Breast Cancer — Jacinto Convit World Organization Inc.
- Study on the Effectiveness and Safety of Different Treatment Combinations for Advanced Breast Cancer — Hoffmann-La Roche
- Study Comparing DB-1303/BNT323 with Chemotherapy for HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer — DualityBio Inc.
- Study on Disitamab Vedotin Alone or With Other Cancer Drugs for Solid Tumors — Seagen Inc.
- A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer — Memorial Sloan Kettering Cancer Center
- Study on Lenvatinib, Pembrolizumab, and Fulvestrant for Breast Cancer — Memorial Sloan Kettering Cancer Center
- Study on Radiation Therapy with Pembrolizumab and Olaparib for Women with Certain Types of Breast Cancer — Memorial Sloan Kettering Cancer Center
- Study on Samuraciclib and Fulvestrant for Advanced Breast Cancer in Adults — Carrick Therapeutics Limited
- Study on Tucatinib Before Surgery for People with HER2+ Cancers That Have Spread to the Brain — Memorial Sloan Kettering Cancer Center
- Study on U3-1402 (Patritumab Deruxtecan) for Patients with Metastatic Breast Cancer — SCRI Development Innovations, LLC
- Study on Adding Targeted Radiation Therapy to Standard Drug Treatment for Breast Cancer — Memorial Sloan Kettering Cancer Center
- Study on Inavolisib and Phesgo for Treating Advanced HER2-Positive Breast Cancer with PIK3CA Mutation — Hoffmann-La Roche
- Study on Alpelisib, iNOS Inhibitor, and Nab-paclitaxel for Patients with HER2 Negative Metaplastic Breast Cancer — The Methodist Hospital Research Institute
- Open-Label Study of Eribulin for Treating Advanced Breast Cancer — Eisai Inc.
- Study on Anastrozole, Fulvestrant, and Abemaciclib for HR+HER2- Metastatic Breast Cancer — University of California, Irvine
- Study on Finding the Right Dose of Zongertinib with Trastuzumab Deruxtecan or Trastuzumab Emtansine for Treating HER2+ Cancer That Has Spread — Boehringer Ingelheim
- Study on SV-BR-1-GM and Retifanlimab Combination for Advanced Breast Cancer — BriaCell Therapeutics Corporation
- Study on Using Targeted Radiation Therapy for High-Risk Spine Cancer Spread — Stony Brook University
- Study on ELACESTRANT for Men and Women with Advanced Estrogen Receptor Positive, HER-2 Negative Breast Cancer — Stemline Therapeutics, Inc.
- ERADICATE: Study of Elacestrant and Trastuzumab Deruxtecan for Advanced Breast Cancer Resistant to CDK4/6 Inhibitors and Hormone Therapy — Sarah Sammons, MD
- Study on Evexomostat with PI3K or AKT Inhibitor and Fulvestrant for Women with PI3K Alteration and HR+/HER2- Breast Cancer — SynDevRx, Inc.
- Expanded Access Program for Abemaciclib in Treating Metastatic Breast Cancer — Eli Lilly and Company
- Study on Using Gene Signatures to Guide Treatment for Hormone Receptor-Positive Metastatic Breast Cancer — Sonya Reid
- Study on HER2-BATs and Pembrolizumab for Treating Metastatic Breast Cancer — University of Virginia
- Study on Using Stereotactic Body Radiotherapy (SBRT) with Standard Treatment for Cancer That Has Spread — Memorial Sloan Kettering Cancer Center
- Study on Using Circulating Tumor DNA to Predict Early Treatment Changes for Patients with Stage IV Breast Cancer — University of Miami
- Study on Neratinib and Capmatinib Combination for Metastatic and Inflammatory Breast Cancer with Abnormal HER-family and c-Met Pathway Activity — M.D. Anderson Cancer Center
- Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer — University of Alabama at Birmingham
- Onvansertib + Paclitaxel in TNBC — Antonio Giordano, MD
- Study Comparing OP-1250 (Palazestrant) with Standard Treatments for Advanced ER+/HER2- Breast Cancer — Olema Pharmaceuticals, Inc.
- Study on Elacestrant Combination Therapy for Patients with Metastatic Breast Cancer — Stemline Therapeutics, Inc.
- Study on Pembrolizumab and Targeted Brain Radiation for Breast Cancer Patients with Brain Metastases — Weill Medical College of Cornell University
- Study on Oral PMD-026 for Patients with Metastatic Breast Cancer — Phoenix Molecular Designs
- Phase 1/2 Study of EP0062 for Patients with Advanced or Metastatic Androgen Receptor Positive Breast Cancer — Ellipses Pharma
- Study on High-Dose Methotrexate for Breast Cancer with Leptomeningeal Metastasis — Wake Forest University Health Sciences
- Study Comparing Ribociclib and Palbociclib for Advanced HER2-Enriched Breast Cancer — SOLTI Breast Cancer Research Group
- Study for Continued Access to Ribociclib — Novartis Pharmaceuticals
- Study on the Safety and Effects of ONC-392 Alone and with Anti-PD-1 in Advanced Solid Tumors and Non-Small Cell Lung Cancer — OncoC4, Inc.
- Study on Scalp Cooling for Hair Loss Prevention in Metastatic Breast Cancer — Dana-Farber Cancer Institute
- Study on Sequencing Antibody Drug Conjugates in ER+/HER2 Low Metastatic Breast Cancer — Reshma L. Mahtani, D.O.
- Phase II Study of Carboplatin with or without Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers — Kathy Miller
- Study on Palliative Radiation and Pembrolizumab for Unresectable Metastatic Stage IV Breast Cancer — University of Louisville
- Study on Bria-IMT Regimen and Checkpoint Inhibitor vs. Doctor's Choice in Advanced Metastatic Breast Cancer — BriaCell Therapeutics Corporation
- Study to Evaluate CCS1477 in Advanced Tumors — CellCentric Ltd.
- STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER) — Dartmouth-Hitchcock Medical Center
- Study on 225Ac-DOTATATE (RYZ101) Alone and with Pembrolizumab for Advanced or Metastatic Breast Cancer with SSTRs — RayzeBio, Inc.
- Study on Vaccination with Flt3L, Radiation, and Poly-ICLC for Cancer Treatment — Icahn School of Medicine at Mount Sinai
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Metastatic Breast Cancer to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.